News Medical on MSN19h
Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatmentA groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...
A monoclonal T-cell receptor (TCR ... given the frequency of viral infections in patients with multiple myeloma after CAR T-cell therapy. The clonal TCRβ CDR3 sequence from both patients did ...
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...
CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...
A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...
T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback